Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunotech BiopharmHKSE:06978 17 Current Ratio is 0.35 as of Dec. 2025, which is 66% below its 10-year median of 1.03. GuruFocus rates HKSE:06978 with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Immunotech Biopharm ranks worse than 93.26% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Immunotech Biopharm's current ratio for the quarter that ended in Dec. 2025 was 0.35.
Immunotech Biopharm has a current ratio of 0.35. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Immunotech Biopharm has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Immunotech Biopharm's Current Ratio or its related term are showing as below:
HKSE:06978'
s Current Ratio Range Over the Past 10 Years
Min: 0.2 Med: 1.03 Max: 27.95
Current: 0.35
During the past 8 years, Immunotech Biopharm's highest Current Ratio was 27.95. The lowest was 0.20. And the median was 1.03.
HKSE:06978's Current Ratio is ranked worse than 93.26% of 1409
companies
in the Biotechnology industry
Industry Median: 3.85
vs HKSE:06978: 0.35
Immunotech Biopharm (HKSE:06978) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Immunotech Biopharm Current Ratio Related Terms
Immunotech Biopharm Current Ratio Historical Data
* Premium members only.
The historical data trend for Immunotech Biopharm's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:06978 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, Immunotech Biopharm's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunotech Biopharm Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Current Ratio distribution charts can be found below:
* The bar in red indicates where Immunotech Biopharm's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunotech Biopharm (HKSE:06978) has a Current Ratio of 0.35 as of Dec. 2025. This is 66% below median its historical median of 1.03. Over the past decade, Immunotech Biopharm's Current Ratio has ranged from 0.20 to 27.95. According to the industry distribution chart, Immunotech Biopharm ranks #1314 out of 1409 companies in the Biotechnology industry, placing it in the top 93.3%.
Is Immunotech Biopharm's Current Ratio too high?
Immunotech Biopharm's current Current Ratio of 0.35 is 66% below median its 10-year median of 1.03. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 27.95. The Biotechnology industry median Current Ratio is 3.85. Immunotech Biopharm's value of 0.35 is 90.9% below this industry median. Based on the distribution chart, Immunotech Biopharm ranks #1314 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immunotech Biopharm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Immunotech Biopharm's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immunotech Biopharm ranks #1314 out of 1409 companies for Current Ratio. This places Immunotech Biopharm in the lower half of its industry. The industry median Current Ratio is 3.85. Immunotech Biopharm's value of 0.35 is 90.9% below this benchmark. Historically, Immunotech Biopharm's own Current Ratio has ranged from 0.20 to 27.95 over the past decade. While the company's 10-year median is 1.03 vs. the industry median of 3.85, Immunotech Biopharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunotech Biopharm's current Current Ratio of 0.35 is 90.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunotech Biopharm's current Current Ratio is 0.35, which is 66% below median its own 10-year median of 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunotech Biopharm stock overvalued right now?
Immunotech Biopharm (HKSE:06978) has a current Current Ratio of 0.35. The current Current Ratio is 0.35, which is 66% below median its 10-year median of 1.03 and 90.9% below the Biotechnology industry median of 3.85. Immunotech Biopharm's overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Immunotech Biopharm (HKSE:06978), the current Current Ratio is 0.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
17GF Score
Get the complete analysis for HKSE:06978
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06978 has been successfully added to your 
